Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR6T8L)

Drug Name

COM902 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting V-set and immunoglobulin domain-containing protein 9 (TIGIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ociperlimab	DMEDSVJ	Non-small-cell lung cancer	2C25.Y	Phase 3	[3]
AB154	DMUES7Y	Non-small-cell lung cancer	2C25	Phase 3	[4]
GSK4428859	DMIOIU8	Aggressive cancer	2A00-2F9Z	Phase 2	[5]
Rilvegostomig	DMDWCM2	Non-small-cell lung cancer	2C25	Phase 1/2	[6]
ASP8374	DMA71OL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
SEA-TGT	DM7GUH3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
M6223	DM6J085	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
V-set and immunoglobulin domain-containing protein 9 (TIGIT)	TTWNL74	TIGIT_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04354246) COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
2	COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26.
3	Clinical pipeline report, company report or official report of BeiGene.
4	Clinical pipeline report, company report or official report of Arcus Biosciences.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline
6	ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Clinical pipeline report, company report or official report of Seagen.
9	ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.